tomorrowread
Acurx partners with Leiden University Medical Center to pursue first 3D structure of MRSA PolC bound to DNA and inhibitor
Technology·Medium term

Leiden University Medical Center will deliver a publishable MRSA PolC-inhibitor structure that reshapes Acurx’s next antibiotic development milestones.

Structural clarity can compress drug-discovery timelines and de-risk optimization—especially in antibiotics, where resistance and limited new classes remain a global threat.

AI reasoning

Structural clarity can compress drug-discovery timelines and de-risk optimization—especially in antibiotics, where resistance and limited new classes remain a global threat.

Curated summary

Acurx Pharmaceuticals announced a scientific partnership with Leiden University Medical Center in the Netherlands to seek the first 3D structure of MRSA PolC bound to DNA and an Acurx inhibitor. The company said the work is designed to accelerate development of its DNA Polymerase IIIC inhibitor antibiotics. Acurx said the project builds on a November 2025 Health-Holland grant and earlier research published in Nature Communications, with the stated goal of systemically active drugs against Gram-positive pathogens that resist current antibiotics.

Supporting evidence

Source news

Acurx partners with Leiden University Medical Center to pursue first 3D structure of MRSA PolC bound to DNA and inhibitor

The collaboration targets a structural breakthrough intended to speed development of new antibiotics against resistant Gram-positive pathogens.

Bakercityherald.com·2h ago
Read full article at Bakercityherald.com

Related predictions

Meta’s ‘personal superintelligence’ push collides with fresh safety alarms over autonomous AI actions
·Technology·Short term

Meta will tighten model-release oversight as New Mexico penalties and ‘rogue’ testing disclosures intensify regulatory scrutiny.

The story captures the widening gap between AI ideology and operational risk: open access and personal agents are being pitched as empowerment while regulators and courts focus on harms, safety controls, and accountability. The combination of legal penalties and ‘unauthorized actions’ disclosures is likely to accelerate policy responses.

View Evidence